Table of Contents
- Trials overview
- Conditions and patient groups
- Trial phases and designs
- Main endpoints and what they mean
- How Loperamide Hydrochloride is used in these studies
- Patient-focused summary
Trials overview
The source data includes multiple interventional studies that mention Loperamide Hydrochloride. These trials investigate different diseases and treatment strategies, and Loperamide Hydrochloride is used either as a supportive medicine, a comparison treatment, or part of a study plan.[1][2]
The studies listed are in several phases, from early testing to later confirmatory research. They include completed and authorised trials, showing that the medicine appears in active research across different patient groups.[1][2]
Conditions and patient groups
The trials cover a wide range of conditions, including breast cancer, myelofibrosis, prostate cancer, endometrial cancer, irritable bowel syndrome, bile acid diarrhoea, gastroenteropancreatic neuroendocrine tumours, ischemic stroke, and type 2 diabetes.[1][2]
Most trials are in adults with a specific diagnosis. Some studies focus on advanced disease, such as metastatic or recurrent cancer, while others focus on early-stage disease or symptom control in people with bowel problems.[1][2]
One breast cancer study specifically includes people with early-stage HER2 positive, hormone receptor positive breast cancer after trastuzumab-based therapy. Another study includes adults with non-constipated irritable bowel syndrome, and another targets people with moderate-to-severe bile acid diarrhoea.[1][2]
Trial phases and designs
The trials using Loperamide Hydrochloride include Phase 1, Phase 2, Phase 3, and Phase 4 research.[1][2]
Phase 1 research in the source data is the JAZMINE study, which looks at safety, the maximum tolerated dose, and the recommended Phase II dose for zanidatamab combinations in HER2-positive advanced breast cancer.[1]
Phase 2 studies include research in breast cancer, prostate cancer, ischemic stroke, gastroenteropancreatic neuroendocrine tumours, and bile acid diarrhoea. These studies often ask whether a treatment works and how safe it is in the target group.[1][2]
Phase 3 studies include work in myelofibrosis, irritable bowel syndrome, and early-stage HER2 positive breast cancer. These later studies usually compare treatment strategies in larger groups and focus on stronger proof of benefit.[1][2]
Phase 4 research in the source data includes a study in advanced or recurrent endometrial cancer. This stage often looks at real-world use and further safety or effectiveness questions after earlier testing.[1]
Main endpoints and what they mean
Different trials measure different primary outcomes, which are the main results the study wants to see.[1]
In the irritable bowel syndrome study, the main endpoint is the change in the IBS-SSS total score. The IBS-SSS is a symptom scale, which means it is a score that shows how severe the bowel symptoms are.[1]
In the bile acid diarrhoea study, the main endpoint is remission, which means the diarrhoea improves enough to meet the study’s criteria for response.[1]
In the myelofibrosis study, the main endpoints are spleen volume reduction and total symptom score reduction. Spleen volume reduction means the spleen becomes smaller on imaging, and total symptom score measures how much the symptoms improve.[1]
In the endometrial cancer study, the main endpoint in Part 2 is progression-free survival, which means the time before the cancer gets worse or the person dies.[1]
Other studies measure outcomes such as HbA1c change in type 2 diabetes, modified Rankin Scale shift in ischemic stroke, and rates of diarrhoea or neutropenia in cancer treatment studies.[1][2]
How Loperamide Hydrochloride is used in these studies
In the source data, Loperamide Hydrochloride is not being studied as a stand-alone drug for every condition. In some trials, it is used to help control diarrhoea, especially when another cancer treatment is known to cause bowel side effects.[1]
For example, one breast cancer study tests sacituzumab govitecan together with Loperamide Hydrochloride and G-CSF, and its co-primary endpoints are diarrhoea and neutropenia rates. Neutropenia means a low number of neutrophils, a type of white blood cell that helps fight infection.[1]
Another study in early-stage HER2 positive breast cancer compares neratinib strategies with Loperamide Hydrochloride to see how often treatment is stopped because of diarrhoea.[1]
In some trials, the medicine is used as a matching placebo or control product, while in others it is part of supportive care during treatment. This means the trial is often testing a broader treatment plan, not only Loperamide Hydrochloride itself.[1][2]
Patient-focused summary
If you see Loperamide Hydrochloride in a clinical trial record, it usually means the study is looking at symptom control, treatment tolerance, or a comparison between treatment plans. The target patients are adults with specific diseases, and the trial aims may include safety, symptom improvement, or disease control.[1][2]
The most important thing to notice is the study question. Some trials ask whether a treatment works better, while others ask whether side effects like diarrhoea can be reduced or whether a treatment can be better tolerated.[1]
